Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company, has received new patent from the US Patent & Trademark Office that protects the composition of matter of obatoclax through 2025.
Subscribe to our email newsletter
One of Gemin X’s lead pipeline programs, obatoclax is an oncology treatment based on programmed cell death, or apoptosis, and has the potential to be a first-in-class pan Bcl-2 inhibitor.
Obatoclax is currently in Phase II clinical trials for the treatment of elderly acute myeloid leukemia and the treatment of small cell lung cancer.
Glenn Gormley, president and CEO of Gemin X, said: “This key patent is core to our overall IP strategy and provides important protection for our obatoclax program. We are excited about the potential of obatoclax – used as a single agent or in combination with other therapies – to treat a range of cancers and we look forward to advancing this program.”